The demo achieved each its Principal endpoints, with semaglutide 2.four mg demonstrating statistically important and excellent advancements in liver fibrosis without worsening of steatohepatitis, together with resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH in co